Our Services
Medical Information
Helpful Resources
Published on: 9/13/2026
Mild burning, urgency, or frequency can linger 2 to 3 days into nitrofurantoin, since most people improve within 48 to 72 hours but full symptom relief often takes the entire 5 day course. Warning signs that suggest something more than slow healing include fever, chills, flank or back pain, nausea, vomiting, blood in the urine that is worsening, or symptoms that are no better or getting worse by day 3, which can point to a resistant bacteria, a kidney infection, or a different diagnosis such as vaginitis, an STI, or interstitial cystitis. There are several factors to consider, including your age, pregnancy status, kidney function, and whether you have had recurrent infections, so see below to understand the details that matter for your situation.
Because "normal" depends heavily on your specific timeline and risk factors, a quick assessment can help you tell ordinary healing from a signal that you need to be re-evaluated before your course ends. Take a free, instant, online symptom check to clarify what your lingering symptoms may mean and what steps to take next.
Last reviewed for medical accuracy: 09/12/2026
If you’ve been taking nitrofurantoin for a urinary tract infection (UTI) and still feel burning, urgency, or discomfort after three days, you’re not alone. It’s natural to wonder whether your treatment is working or if you need to act fast. Below, we explain what to expect, why symptoms may linger, and when to seek further care.
Nitrofurantoin is a widely prescribed antibiotic specifically targeting common UTI bacteria, such as Escherichia coli. Unlike broad-spectrum antibiotics, nitrofurantoin concentrates in the urine, attacking bacteria where they live. You’ll usually find it under brand names like Macrobid® or Macrodantin®, or simply as “nitrofurantoin.”
Key points:
Most people begin to feel better within 24–48 hours of starting nitrofurantoin. However, responses vary:
Having some lingering discomfort at day 3 isn’t unusual, especially if your infection was moderate or if you started treatment a bit later in the course of your illness.
Still dealing with UTI symptoms on day three? Several factors can play a role:
It’s okay if you’re not 100% symptom-free at three days—just keep an eye on warning signs:
Signs that may resolve on their own with continued nitrofurantoin:
Red flags that need prompt medical attention:
Stay on Course
Continue taking nitrofurantoin exactly as prescribed. Antibiotics lose effectiveness if doses are skipped.
Hydrate
Drinking water helps flush bacteria out. Aim for at least 8 cups (about 2 liters) spread throughout the day.
Use Symptom Relief
Over-the-counter pain relievers (acetaminophen or ibuprofen) can ease discomfort.
A heating pad on your lower abdomen may help relax bladder spasms.
Monitor Closely
Keep a simple diary of:
Consider Further Testing
If symptoms persist beyond five days:
Still uncertain about your symptoms? You might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It’s a quick way to understand potential causes and next steps from the comfort of your home.
Once you resolve this infection, these habits can help cut down on recurrences:
Even if you don’t have major warning signs, reach out if:
If you develop severe symptoms—high fever, vomiting, severe back pain, or any life-threatening signs—please speak to a doctor or go to the nearest emergency department immediately.
Remember, it’s not uncommon to still have some UTI discomfort three days into nitrofurantoin therapy. In most cases, continued treatment and self-care will lead to full recovery. If your symptoms worsen or new red-flag signs appear, don’t hesitate to consult your healthcare provider.
(References)
* Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. Am J Obstet Gynecol. 2018 Jul;219(1):40-51. doi: 10.1016/j.ajog.2017.12.231. Epub 2018 Jan 2. PMID: 29305250.
* Huttner A, Kowalczyk A, Turjeman A, Babich T, Brossier C, Eliakim-Raz N, Kosiek K, Martinez de Tejada B, Roux X, Shiber S, Theuretzbacher U, von Dach E, Yahav D, Leibovici L, Godycki-Cwirko M, Mouton JW, Harbarth S. Effect of 5-Day Nitrofurantoin vs Single-Dose Fosfomycin on Clinical Resolution of Uncomplicated Lower Urinary Tract Infection in Women: A Randomized Clinical Trial. JAMA. 2018 May 1;319(17):1781-1789. doi: 10.1001/jama.2018.3627. PMID: 29710295; PMCID: PMC6134435.
* Milazzo E, Orellana G, Briceño-Bierwirth A, Korrapati VK. Acute lung toxicity by nitrofurantoin. BMJ Case Rep. 2021 Apr 14;14(4). doi: 10.1136/bcr-2020-237571. Epub 2021 Apr 14. PMID: 33853812; PMCID: PMC8054053.
* Konwar M, Gogtay NJ, Ravi R, Thatte UM, Bose D. Evaluation of efficacy and safety of fosfomycin versus nitrofurantoin for the treatment of uncomplicated lower urinary tract infection (UTI) in women - A systematic review and meta-analysis. J Chemother. 2022 May;34(3):139-148. doi: 10.1080/1120009X.2021.1938949. Epub 2021 Jun 21. PMID: 34151754.
* Mahdizade Ari M, Dashtbin S, Ghasemi F, Shahroodian S, Kiani P, Bafandeh E, Darbandi T, Ghanavati R, Darbandi A. Nitrofurantoin: properties and potential in treatment of urinary tract infection: a narrative review. Front Cell Infect Microbiol. 2023;13:1148603. doi: 10.3389/fcimb.2023.1148603. Epub 2023 Jul 27. PMID: 37577377; PMCID: PMC10414118.
* Frimodt-Møller N, Bjerrum L. Treating urinary tract infections in the era of antibiotic resistance. Expert Rev Anti Infect Ther. 2023 Jul-Dec;21(12):1301-1308. doi: 10.1080/14787210.2023.2279104. Epub 2023 Nov 24. PMID: 37922147.
* Wagenlehner F, Perry CR, Hooton TM, Scangarella-Oman NE, Millns H, Powell M, Jarvis E, Dennison J, Sheets A, Butler D, Breton J, Janmohamed S. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. Lancet. 2024 Feb 24;403(10428):741-755. doi: 10.1016/S0140-6736(23)02196-7. Epub 2024 Feb 8. PMID: 38342126.
* Kurotschka PK, Gágyor I, Ebell MH. Acute Uncomplicated UTIs in Adults: Rapid Evidence Review. Am Fam Physician. 2024 Feb;109(2):167-174. PMID: 38393801.
* Gkiourtzis N, Stoimeni A, Glava A, Chantavaridou S, Michou P, Cheirakis K, Lalayiannis AD, Hulton SA, Tramma D. Prophylaxis Options in Children With a History of Recurrent Urinary Tract Infections: A Systematic Review. Pediatrics. 2024 Dec 1;154(6). doi: 10.1542/peds.2024-066758. PMID: 39492618.
* Llor C, Monfà R, Garcia-Sangenís A, Leiva A, Marín-Cañada J, Sánchez-Calavera MA, Moragas A, Aguilar-Sánchez M, Troncoso-Mariño A, Rodríguez-Barrientos R, Molero JM, Ouchi D, Miranda-Jiménez C, Fernández-García S, Morros R. Clinical and bacteriological effectiveness of three different short-course antibiotic regimens and single-dose fosfomycin for uncomplicated lower urinary tract infections in women (SCOUT): a pragmatic, multicentre, open-label, randomised clinical trial. Lancet. 2026 Apr 25;407(10539):1603-1613. doi: 10.1016/S0140-6736(25)02171-3. Epub 2026 Apr 20. PMID: 42026010.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.